TY - JOUR
T1 - Retrospective review of 19 patients with lentigo maligna melanoma
AU - Hong, Won Jin
AU - Jang, Hong Sun
AU - Lee, Sang Hee
AU - Lee, Sang Eun
AU - Chung, Kee Yang
AU - Roh, Mi Rjung
PY - 2016
Y1 - 2016
N2 - Background: Lentigo maligna melanoma (LMM) is a subtype of melanoma that typically develops on sun-damaged skin. LMM is estimated to comprise 4 - 15S5 of melanomas, but the prevalence is known to be relatively lower in the Korean population than in the Caucasian population. Objective: To review the clinico-pathologic features and treatment outcomes of Korean patients with LMM. Methods: Nineteen patients diagnosed with LMM during 2003 ~ 2015, in the Yonsei University Health System, were included in this study. The age and sex of the patients, lesion location, thickncss (Breslow), stage, treatment methods, BRAF, NRAS, and KIT mutation status, and survival rates were analyzed. Results: Among the 19 Korean patients, 11 were male and 8 were female. The median age was 59.2 years. The most common site was the cheek (47.4%), followed by the scalp, eyelid, nose, forehead, lip, and neck. At the time of diagnosis, 13 patients were in localized stages (5 patients, stage 0; 3 patients, stage I; and 5 patients, stage II) and 6 patients were in advanced stages (3 patients, stage 111; and 3 patients, stage IV). Patients in the localized stages showed better overall survival (OS) than those in the advanced stages (p=0.012). Nine patients were treated with a wide cxcision, and 6 using Mohs micrographic surgery. Three patients received high-dose interferon-A therapy; 6, chemotherapy; and 4, radiotherapy. Two patients in stage 0 were treated with topical ingenol mcbutatc. Two patients had BRAF V600E mutation; I, NRAS (J12R mutation; and 1, KIT mutation. Median OS of the patients was 40.8 months. Conclusion: Our analysis provides additional information about clinical characteristics, treatment, and prognosis of LMM in Korean patients.
AB - Background: Lentigo maligna melanoma (LMM) is a subtype of melanoma that typically develops on sun-damaged skin. LMM is estimated to comprise 4 - 15S5 of melanomas, but the prevalence is known to be relatively lower in the Korean population than in the Caucasian population. Objective: To review the clinico-pathologic features and treatment outcomes of Korean patients with LMM. Methods: Nineteen patients diagnosed with LMM during 2003 ~ 2015, in the Yonsei University Health System, were included in this study. The age and sex of the patients, lesion location, thickncss (Breslow), stage, treatment methods, BRAF, NRAS, and KIT mutation status, and survival rates were analyzed. Results: Among the 19 Korean patients, 11 were male and 8 were female. The median age was 59.2 years. The most common site was the cheek (47.4%), followed by the scalp, eyelid, nose, forehead, lip, and neck. At the time of diagnosis, 13 patients were in localized stages (5 patients, stage 0; 3 patients, stage I; and 5 patients, stage II) and 6 patients were in advanced stages (3 patients, stage 111; and 3 patients, stage IV). Patients in the localized stages showed better overall survival (OS) than those in the advanced stages (p=0.012). Nine patients were treated with a wide cxcision, and 6 using Mohs micrographic surgery. Three patients received high-dose interferon-A therapy; 6, chemotherapy; and 4, radiotherapy. Two patients in stage 0 were treated with topical ingenol mcbutatc. Two patients had BRAF V600E mutation; I, NRAS (J12R mutation; and 1, KIT mutation. Median OS of the patients was 40.8 months. Conclusion: Our analysis provides additional information about clinical characteristics, treatment, and prognosis of LMM in Korean patients.
UR - http://www.scopus.com/inward/record.url?scp=85021306721&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021306721&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:85021306721
SN - 0494-4739
VL - 54
SP - 769
EP - 775
JO - Korean Journal of Dermatology
JF - Korean Journal of Dermatology
IS - 10
ER -